<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cutaneous squamous cell carcinoma: Primary and secondary prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cutaneous squamous cell carcinoma: Primary and secondary prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cutaneous squamous cell carcinoma: Primary and secondary prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean Lee Lim, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maryam Asgari, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Stern, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">June K Robinson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1907876582"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cutaneous squamous cell carcinoma (cSCC) is the second most common nonmelanoma (keratinocyte) cancer after basal cell carcinoma, accounting for approximately 20 percent of all skin cancers [<a href="#rid1">1</a>]. Its incidence is increasing worldwide; in the United States, it has been estimated that over 700,000 persons were treated for cSCC in 2012 [<a href="#rid2">2</a>]. As the diagnosis and treatment of keratinocyte carcinomas imposes a high burden on health care systems, there is a need for effective primary and secondary prevention strategies [<a href="#rid3">3</a>].</p><p>Cumulative ultraviolet radiation exposure, either occupational or recreational, is the single most important risk factor for cSCC, especially in populations with lighter skin pigmentation. Additional risk factors include genetic predisposition, age, other environmental exposures (eg, arsenic, ionizing radiations), and immunosuppression. (See  <a class="medical medical_review" href="/d/html/5337.html" rel="external">"Cutaneous squamous cell carcinoma: Epidemiology and risk factors"</a>.)</p><p>Primary prevention is aimed at reducing the exposure to known risk factors by using behavioral and environmental interventions, such as decreasing ultraviolet light exposure or arsenic contamination of water. Secondary prevention involves early detection and treatment of skin cancer and precursor lesions. Chemoprevention is a secondary prevention strategy for patients at high risk of developing multiple cSCCs (eg, patients with a history of cSCC, extensive sun-induced skin damage and actinic keratosis, immunosuppressed patients).</p><p>This topic will review primary and secondary prevention strategies for cSCC. The prevention and management of skin cancer in organ transplant recipients is discussed separately. The risk factors, diagnosis, and management of cSCC are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5337.html" rel="external">"Cutaneous squamous cell carcinoma: Epidemiology and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16225.html" rel="external">"Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5339.html" rel="external">"Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13713.html" rel="external">"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13712.html" rel="external">"Actinic keratosis: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5336.html" rel="external">"Treatment of actinic keratosis"</a>.)</p><p></p><p class="headingAnchor" id="H1159431069"><span class="h1">SUN PROTECTION</span><span class="headingEndMark"> — </span>Minimizing ultraviolet light exposure by limiting the time spent in the sun in peak hours, using sunscreen, and wearing protective clothing is the most effective primary prevention strategy to reduce the incidence of cSCC and its precursors (actinic keratoses) in individuals at risk. Behavioral interventions have been shown to increase sun protection behaviors in children, adolescents, and young adults. However, there is little evidence that such interventions are associated with a reduction in the incidence and outcomes of skin cancer [<a href="#rid4">4</a>].</p><p>Evidence from randomized trials indicates that regular use of sunscreen reduces the risk of cSCC and actinic keratoses [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial that included 588 participants with previous actinic keratoses, individuals who used daily sun protection factor (SPF) 17 sunscreen for one summer had fewer new actinic keratoses at seven months compared with the placebo group (1.6 versus 2.3, rate ratio [RR] 0.6, 95% CI 0.54-0.71) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/13712.html" rel="external">"Actinic keratosis: Epidemiology, clinical features, and diagnosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Nambour trial that included 1621 residents randomized to use daily SPF 15 sunscreen or to use sunscreen at their usual discretionary frequency, daily use of sunscreen for 4.5 years was associated with a significantly lower incidence of cSCCs (1115 versus 1832 per 100,000 compared with no daily sunscreen) [<a href="#rid7">7</a>]. In contrast, no difference was observed in the incidence of basal cell carcinomas (BCCs).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An extended follow-up study of the Nambour trial showed that cSCC incidence rates, both in terms of persons newly affected and number of tumors, were reduced by 35 and 38 percent, respectively, in the former sunscreen treatment group compared with the control group after eight years of follow-up (RR 0.65, 95% CI 0.43-0.98 and RR 0.68, 95% CI 0.38-0.99) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of data from the Norwegian Women and Cancer Study that included 148,781 women, of whom 653 were diagnosed with cSCC over an average follow-up of 14.3 years, showed no difference in the risk of cSCC among users of sunscreens with an SPF ≥15 versus an SPF &lt;15 at any latitudes (hazard ratio [HR] 1.02, 95% CI 0.82-1.27) and in lower-latitude settings (HR 1.05, 95% CI 0.84-1.32) [<a href="#rid9">9</a>]. However, these results must be interpreted with caution, as information on frequency of sunscreen use, number of hours spent outdoors, and additional sun protection behavior (eg, sun avoidance, use of protective clothing) was not available. </p><p></p><p>Sunscreens and other sun protection measures are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p class="headingAnchor" id="H2401156852"><span class="h1">IN-OFFICE SCREENING AND SELF-SURVEILLANCE</span><span class="headingEndMark"> — </span>Patients with multiple actinic keratoses and/or a history of cSCC should be counseled regarding the need of periodic skin examinations by a clinician with experience in the detection and treatment of skin cancer and regular skin self-examinations [<a href="#rid10">10,11</a>]. These measures may help in detecting new primary tumors at an early stage, when they can be easily treated. (See  <a class="medical medical_review" href="/d/html/4845.html" rel="external">"Screening for melanoma in adults and adolescents", section on 'Patient self-examination'</a>.)</p><p class="headingAnchor" id="H1882208041"><span class="h1">CHEMOPREVENTION</span><span class="headingEndMark"> — </span>Chemoprevention is a secondary prevention strategy for patients at high risk of developing nonmelanoma skin cancer [<a href="#rid12">12</a>]. It is based on the concept that topical or systemic treatments may prevent the progression of subclinical precursor lesions into invasive carcinoma. Thus, chemoprevention may be appropriate in patients with a history of an invasive cSCC and extensive sun-damaged skin with numerous actinic keratoses and in select patients with a history of multiple invasive cSCCs, including solid organ transplant recipients. (See  <a class="medical medical_review" href="/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients", section on 'Chemoprevention for squamous cell carcinoma'</a> and  <a class="medical medical_review" href="/d/html/5336.html" rel="external">"Treatment of actinic keratosis", section on 'Multiple thin lesions/field cancerization'</a>.)</p><p class="headingAnchor" id="H3020261675"><span class="h2">Systemic agents</span></p><p class="headingAnchor" id="H2378505944"><span class="h3">Oral retinoids</span><span class="headingEndMark"> — </span>Retinoids are vitamin A derivatives that are available in topical and oral preparations. Oral retinoids inhibit cSCC cell growth in vitro and may reduce the development of cSCC tumors in high-risk populations, such as those with a history of multiple nonmelanoma skin cancers [<a href="#rid13">13,14</a>], genetic disorders such as xeroderma pigmentosum [<a href="#rid15">15,16</a>], transplant recipients [<a href="#rid17">17,18</a>], and patients exposed to high cumulative levels of psoralen plus ultraviolet A (PUVA) therapy [<a href="#rid19">19</a>]. However, the adverse effects of systemic retinoids, including hypertriglyceridemia and hepatic toxicity, are an important limitation to their long-term use.</p><p>Examples of studies that have evaluated the use of oral retinoids for the prevention of cSCC include:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 2297 adults with a prior history of &gt;10 actinic keratoses or ≥2 cSCCs were randomly assigned to 25,000 international units of oral retinol daily or a placebo. At an average follow-up of four years, the active treatment group had a significantly lower rate of new cSCCs (hazard ratio [HR] 0.74, 95% CI 0.56-0.99) [<a href="#rid14">14</a>]. However, this dose of retinol was associated with an 11 percent higher triglyceride level and 3 percent higher cholesterol level, which may increase coronary artery disease risk [<a href="#rid20">20</a>]. Of note, a smaller, randomized trial of 525 patients treated with oral retinol (25,000 units per day), <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a> (5 to 10 mg per day), or placebo for three years found a lack of benefit with both retinol and isotretinoin [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In five patients with xeroderma pigmentosum, 121 tumors occurred in the two-year interval before treatment with oral <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a> compared with 25 in the two years during treatment [<a href="#rid15">15</a>]. Following cessation of therapy, there was an 8.5-fold increase in tumor frequency [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Randomized trials have found variable results for the efficacy of <a class="drug drug_general" data-topicid="9250" href="/d/drug information/9250.html" rel="external">acitretin</a> as a chemopreventive agent in organ transplant recipients [<a href="#rid22">22</a>]. Data from these trials are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients", section on 'Acitretin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among psoriasis patients treated with PUVA, the use of oral retinoids for at least 26 weeks per year was associated with a significantly decreased incidence of cSCC compared with less frequent retinoid use (196 cSCCs/1000 years versus 302 cSCCs/1000 years, respectively) [<a href="#rid19">19</a>]. The benefit was restricted to periods of high usage.</p><p></p><p class="headingAnchor" id="H3847412215"><span class="h3">Nonsteroidal anti-inflammatory drugs</span><span class="headingEndMark"> — </span>Studies in animal models suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) may prevent the development of cSCC, but human studies have led to conflicting results [<a href="#rid23">23-28</a>]. However, a meta-analysis of eight observational studies and one randomized trial found a 15 percent risk reduction associated with the use of nonaspirin NSAIDs (relative risk [RR] 0.85, 95% CI 0.78-0.94) [<a href="#rid29">29</a>].</p><p>Additional studies are necessary to determine whether there is a dose-response relationship between use of NSAIDs and reduction in cSCC risk and whether the beneficial effects on cSCC risk would outweigh the risks of long-term therapy with NSAIDs [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a>.)</p><p class="headingAnchor" id="H2472851036"><span class="h3">Capecitabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a> is a prodrug of 5-fluorourcil that is metabolized by thymidine phosphorylase, which is often overexpressed in certain carcinomas. Low-dose oral capecitabine has been used for chemoprevention in organ transplant recipients who develop more than two cSCCs in six months. Two small case series demonstrated that low-dose capecitabine significantly reduced the incidence of cSCC in organ transplant recipients, with relatively manageable adverse effects [<a href="#rid31">31,32</a>]. (See  <a class="medical medical_review" href="/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients", section on 'Capecitabine'</a>.)</p><p class="headingAnchor" id="H1144547404"><span class="h2">Topical agents</span></p><p class="headingAnchor" id="H2222936042"><span class="h3">Topical retinoids</span><span class="headingEndMark"> — </span>A large, multicenter, randomized trial (n = 1131) sought to investigate the effect of <a class="drug drug_general" data-topicid="10014" href="/d/drug information/10014.html" rel="external">topical tretinoin</a> on the prevention of cSCC and basal cell carcinoma (BCC) [<a href="#rid33">33</a>]. Patients were treated with tretinoin 0.1% cream or a vehicle control for 1.5 to 5.5 years. Treatment with tretinoin was not effective for chemoprevention in this trial; statistically significant differences in the proportions of patients who had developed an invasive cSCC (28 versus 31 percent) or a BCC (53 versus 54 percent) after five years were not detected. The trial was terminated prematurely due to an increase in mortality observed in the treatment group. However, the authors questioned the validity of this finding [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H4038900562"><span class="h3">Topical fluorouracil</span><span class="headingEndMark"> — </span>A single course of topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (daily application for up to four weeks) as "field treatment" for actinic keratosis has been shown to reduce the development of new actinic keratoses, a marker for increased risk of cSCC in older male patients with multiple previous keratinocyte cancers [<a href="#rid35">35-37</a>] (see  <a class="medical medical_review" href="/d/html/5336.html" rel="external">"Treatment of actinic keratosis", section on 'Topical fluorouracil'</a>). However, only a few studies have evaluated topical fluorouracil for the prevention of cSCC in high-risk patients, and its efficacy in this regard remains uncertain:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 932 participants with a history of at least two keratinocyte cancers in the previous five years were instructed to apply topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> 5% cream or vehicle cream twice daily to the face and ears for four weeks (a total of 56 doses) [<a href="#rid38">38</a>]. The primary study endpoints were surgically treated BCC or squamous cell carcinoma (SCC) on the face or ears. Although in the first year following treatment less participants in the treatment group developed a cSCC compared with the placebo group (1 versus 4 percent), no difference was noted between the fluorouracil and control groups in time to the first BCC or cSCC for the overall four-year study period. After a median follow-up time of 2.8 years, the proportions of patients who underwent surgical excision for one or more BCCs or cSCCs were 32 and 11 percent, respectively, in the fluorouracil group and 32 and 12 percent, respectively, in the control group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A small, randomized trial compared the efficacy of a four-day course of topical <a class="drug drug_general" data-topicid="9181" href="/d/drug information/9181.html" rel="external">calcipotriol</a> plus topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> with topical fluorouracil plus vehicle for the prevention of cSCC in 130 patients with 4 to 15 actinic keratoses within a 25 cm<sup>2</sup> area on the face, scalp, or upper extremities [<a href="#rid39">39</a>]. At three years following treatment, fewer patients in the calcipotriol plus topical fluorouracil group than in the control group developed a cSCC on their treated face and scalp (2 out of 30 versus 11 out of 40, respectively; HR 0.22, 95% CI 0.05-0.97). However, these results should be interpreted with caution due to the small sample size of the trial and the large number of patients lost to follow-up.</p><p></p><p class="headingAnchor" id="H259716135"><span class="h3">Imiquimod</span><span class="headingEndMark"> — </span>Field therapy of actinic keratosis with <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> seems to be as effective as topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> in decreasing the risk of developing cSCC in the treated field. Imiquimod 5% cream is typically applied to an involved area of ≤25 cm<sup>2</sup> twice weekly for 16 weeks. (See  <a class="medical medical_review" href="/d/html/5336.html" rel="external">"Treatment of actinic keratosis", section on 'Imiquimod'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective, cohort study from a large health care delivery system in the United States, all patients with actinic keratosis who had been prescribed field treatment with topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (n = 5062) or <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> (n = 638) in 2007 were followed up for the development of any subsequent keratinocyte carcinomas (cSCC or BCC) and site-specific tumors arising in the treated field [<a href="#rid40">40</a>]. A multivariate analysis showed no significant difference between the two treatments in the risks of site-specific keratinocyte carcinomas (HR 0.96, 95% CI 0.81-1.14).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of two randomized trials that included a total of 479 immunocompetent patients with 5 to 10 typical, visible actinic keratosis lesions in one contiguous area of up to 50 cm<sup>2 </sup>on the face or scalp evaluated the long-term efficacy of <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> applied twice daily for 12 weeks compared with two four-week cycles of <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> administered four weeks apart [<a href="#rid41">41</a>]. The primary endpoint (histologic change to a higher histologic grade of actinic keratosis or development of invasive SCC) in the treated area was observed in more patients in the diclofenac group than in the imiquimod group (11 versus 5.4 percent, respectively; absolute risk difference -5.6 percent, 95% CI -10.7 to -0.7) up to 36 months post-treatment.</p><p></p><p class="headingAnchor" id="H3667726516"><span class="h2">Vitamins and dietary supplements</span><span class="headingEndMark"> — </span>Several studies have investigated the association of diet and dietary supplements with the risk of cSCC with uncertain or conflicting results:</p><p class="bulletIndent1"><span class="glyph">●</span>One large, United States, cohort study including nearly 86,000 female nurses and 44,000 male health professionals from the Nurses' Health Study and the Health Professionals Follow-up Study followed up for 14 and 10 years, respectively, concluded that dietary vitamin A, C, and E; folate; and carotenoids have no effect in preventing cSCC [<a href="#rid42">42</a>]. A reanalysis of data from the same cohorts after an additional 16 years of follow-up found that higher intakes of total vitamin A, retinol, and some carotenoids (alfa-carotene, beta-cryptoxanthin, lycopene, and lutein/zeaxanthin) were associated with a modest reduction in cSCC risk, after adjusting for known risk factors for cSCC [<a href="#rid43">43</a>]. However, as participants with higher intake of vitamin A tended to have healthier behaviors (eg, higher levels of physical activity, lower prevalence of smoking and alcohol consumption), a confounding effect of sun protection behaviors (eg, use of sunscreen, sun avoidance), which were not assessed in this study, cannot be excluded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of data from a randomized trial of vitamin D supplementation among Australians aged ≥60 years found that vitamin D supplementation (60,000 international units monthly for five years) did not reduce the incidence of keratinocytic cancer excisions, the incidence of other actinic lesions treated with cryotherapy or serial curettage, or time to first keratinocytic cancer excision [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three randomized trials of <a class="drug drug_general" data-topicid="9127" href="/d/drug information/9127.html" rel="external">beta-carotene</a> supplementation for cSCC prevention showed no protective or harmful effects [<a href="#rid7">7,45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of oral <a class="drug drug_general" data-topicid="9696" href="/d/drug information/9696.html" rel="external">nicotinamide</a> (vitamin B3), a dietary supplement available over the counter, for the prevention of nonmelanoma skin cancer was evaluated in a 2015 phase III, randomized trial [<a href="#rid47">47</a>]. In this study, 386 immunocompetent participants (mean age 66 years) with ≥2 histologically confirmed nonmelanoma skin cancers in the past five years were treated with 500 mg of nicotinamide twice daily or placebo for 12 months. At the end of the study, the rate reduction for cSCC was 30 percent (95% CI 0 to 51 percent). However, no benefit was observed after treatment discontinuation. </p><p></p><p class="bulletIndent1">These results are insufficient to make any recommendation about the use of <a class="drug drug_general" data-topicid="9696" href="/d/drug information/9696.html" rel="external">nicotinamide</a> for the chemoprevention of cSCC. Further studies are needed to evaluate the efficacy and safety of long-term treatment and to establish the optimal dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Self-reported use of grape seed extract as a dietary supplement was associated with a reduced risk for cSCC in a study of 415 patients with cSCC and their matched controls (adjusted odds ratio [OR] 0.26, 95% CI 0.08-0.89) [<a href="#rid48">48</a>]. Further studies are necessary to corroborate these findings prior to a recommendation for the use of grape seed extract for this indication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of an older southwestern population suggested that consumption of D-limonene found in citrus peels and hot black tea was associated with decreased cSCC risk [<a href="#rid49">49</a>]. In contrast, a case-control study of 415 patients with cSCC and their matched controls showed no reduction of cSCC risk amongst those who regularly consumed tea [<a href="#rid50">50</a>].</p><p></p><p class="headingAnchor" id="H2882276457"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120260.html" rel="external">"Society guideline links: Nonmelanoma skin cancer"</a>.)</p><p class="headingAnchor" id="H238211773"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sun protection</strong> – Reducing ultraviolet radiation exposure by limiting the time spent in the sun during peak hours, using sunscreen, and wearing sun-protective clothing is the most effective primary prevention strategy to reduce the incidence of cutaneous squamous cell carcinoma (cSCC) and precursor lesions (actinic keratoses). (See <a class="local">'Sun protection'</a> above and  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and early diagnosis</strong> – Early diagnosis and treatment of cSCC is crucial in high-risk patients with multiple precursor lesions (actinic keratoses) and/or a history of cSCC. High-risk patients should be educated about the importance of periodic skin examinations by a clinician with experience in skin cancer detection and treatment and regular skin self-examinations. (See <a class="local">'In-office screening and self-surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemoprevention</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systemic agents</strong> – Systemic chemoprevention does not have an established role in the prevention of cSCC. While oral retinoids may have some benefit in select high-risk patients, such as organ transplant recipients, their side effects inhibit prolonged use. (See <a class="local">'Systemic agents'</a> above and  <a class="medical medical_review" href="/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Topical agents</strong> – "Field treatment" with topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> may be useful for the long-term control of actinic keratoses in patients with multiple actinic keratoses with or without a history of cSCC. However, their efficacy in the prevention of invasive cSCC remains uncertain. (See <a class="local">'Topical agents'</a> above and  <a class="medical medical_review" href="/d/html/5336.html" rel="external">"Treatment of actinic keratosis"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol 2018; 78:237.</a></li><li><a class="nounderline abstract_t">Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol 2015; 151:1081.</a></li><li><a class="nounderline abstract_t">Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003; 48:425.</a></li><li><a class="nounderline abstract_t">Henrikson NB, Morrison CC, Blasi PR, et al. Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 319:1143.</a></li><li><a class="nounderline abstract_t">Sánchez G, Nova J, Rodriguez-Hernandez AE, et al. Sun protection for preventing basal cell and squamous cell skin cancers. Cochrane Database Syst Rev 2016; 7:CD011161.</a></li><li><a class="nounderline abstract_t">Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993; 329:1147.</a></li><li><a class="nounderline abstract_t">Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354:723.</a></li><li><a class="nounderline abstract_t">van der Pols JC, Williams GM, Pandeya N, et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006; 15:2546.</a></li><li><a class="nounderline abstract_t">Lergenmuller S, Ghiasvand R, Robsahm TE, et al. Sunscreens With High Versus Low Sun Protection Factor and Cutaneous Squamous Cell Carcinoma Risk: A Population-Based Cohort Study. Am J Epidemiol 2022; 191:75.</a></li><li><a class="nounderline abstract_t">Work Group, Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol 2018; 78:560.</a></li><li><a class="nounderline abstract_t">Waldman A, Schmults C. Cutaneous Squamous Cell Carcinoma. Hematol Oncol Clin North Am 2019; 33:1.</a></li><li><a class="nounderline abstract_t">Nemer KM, Council ML. Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer. Dermatol Clin 2019; 37:287.</a></li><li><a class="nounderline abstract_t">DiGiovanna JJ. Retinoid chemoprevention in patients at high risk for skin cancer. Med Pediatr Oncol 2001; 36:564.</a></li><li><a class="nounderline abstract_t">Moon TE, Levine N, Cartmel B, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6:949.</a></li><li><a class="nounderline abstract_t">Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318:1633.</a></li><li><a class="nounderline abstract_t">Kraemer KH, DiGiovanna JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 1992; 19:715.</a></li><li><a class="nounderline abstract_t">McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999; 140:656.</a></li><li><a class="nounderline abstract_t">Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 2005; 141:456.</a></li><li><a class="nounderline abstract_t">Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49:644.</a></li><li><a class="nounderline abstract_t">Cartmel B, Moon TE, Levine N. Effects of long-term intake of retinol on selected clinical and laboratory indexes. Am J Clin Nutr 1999; 69:937.</a></li><li><a class="nounderline abstract_t">Levine N, Moon TE, Cartmel B, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6:957.</a></li><li><a class="nounderline abstract_t">Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005; 152:518.</a></li><li><a class="nounderline abstract_t">Butler GJ, Neale R, Green AC, et al. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005; 53:966.</a></li><li><a class="nounderline abstract_t">Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999; 25:231.</a></li><li><a class="nounderline abstract_t">Wilgus TA, Koki AT, Zweifel BS, et al. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 2003; 38:49.</a></li><li><a class="nounderline abstract_t">Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010; 102:1835.</a></li><li><a class="nounderline abstract_t">Asgari MM, Chren MM, Warton EM, et al. Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol 2010; 146:388.</a></li><li><a class="nounderline abstract_t">Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012; 118:4768.</a></li><li><a class="nounderline abstract_t">Muranushi C, Olsen CM, Pandeya N, Green AC. Aspirin and nonsteroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysis. J Invest Dermatol 2015; 135:975.</a></li><li><a class="nounderline abstract_t">Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071.</a></li><li><a class="nounderline abstract_t">Endrizzi B, Ahmed RL, Ray T, et al. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. Dermatol Surg 2013; 39:634.</a></li><li><a class="nounderline abstract_t">Jirakulaporn T, Endrizzi B, Lindgren B, et al. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant 2011; 25:541.</a></li><li><a class="nounderline abstract_t">Weinstock MA, Bingham SF, Digiovanna JJ, et al. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol 2012; 132:1583.</a></li><li><a class="nounderline abstract_t">Weinstock MA, Bingham SF, Lew RA, et al. Topical tretinoin therapy and all-cause mortality. Arch Dermatol 2009; 145:18.</a></li><li><a class="nounderline abstract_t">Walker JL, Siegel JA, Sachar M, et al. 5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial. J Invest Dermatol 2017; 137:1367.</a></li><li><a class="nounderline abstract_t">Pomerantz H, Hogan D, Eilers D, et al. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. JAMA Dermatol 2015; 151:952.</a></li><li><a class="nounderline abstract_t">Neugebauer R, Levandoski KA, Zhu Z, et al. A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis. J Am Acad Dermatol 2018; 78:710.</a></li><li><a class="nounderline abstract_t">Weinstock MA, Thwin SS, Siegel JA, et al. Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial. JAMA Dermatol 2018; 154:167.</a></li><li><a class="nounderline abstract_t">Rosenberg AR, Tabacchi M, Ngo KH, et al. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight 2019; 4.</a></li><li><a class="nounderline abstract_t">Neugebauer R, Su KA, Zhu Z, et al. Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study. J Am Acad Dermatol 2019; 80:998.</a></li><li><a class="nounderline abstract_t">Gollnick H, Dirschka T, Ostendorf R, et al. Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol 2020; 34:82.</a></li><li><a class="nounderline abstract_t">Fung TT, Spiegelman D, Egan KM, et al. Vitamin and carotenoid intake and risk of squamous cell carcinoma of the skin. Int J Cancer 2003; 103:110.</a></li><li><a class="nounderline abstract_t">Kim J, Park MK, Li WQ, et al. Association of Vitamin A Intake With Cutaneous Squamous Cell Carcinoma Risk in the United States. JAMA Dermatol 2019; 155:1260.</a></li><li><a class="nounderline abstract_t">Ali S, Pham H, Waterhouse M, et al. The effect of vitamin D supplementation on risk of keratinocyte cancer: an exploratory analysis of the D-Health randomized controlled trial. Br J Dermatol 2022; 187:667.</a></li><li><a class="nounderline abstract_t">Frieling UM, Schaumberg DA, Kupper TS, et al. A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study. Arch Dermatol 2000; 136:179.</a></li><li><a class="nounderline abstract_t">Greenberg ER, Baron JA, Stukel TA, et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990; 323:789.</a></li><li><a class="nounderline abstract_t">Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 2015; 373:1618.</a></li><li><a class="nounderline abstract_t">Asgari MM, Chren MM, Warton EM, et al. Supplement use and risk of cutaneous squamous cell carcinoma. J Am Acad Dermatol 2011; 65:1145.</a></li><li><a class="nounderline abstract_t">Hakim IA, Harris RB. Joint effects of citrus peel use and black tea intake on the risk of squamous cell carcinoma of the skin. BMC Dermatol 2001; 1:3.</a></li><li><a class="nounderline abstract_t">Asgari MM, White E, Warton EM, et al. Association of tea consumption and cutaneous squamous cell carcinoma. Nutr Cancer 2011; 63:314.</a></li></ol></div><div id="topicVersionRevision">Topic 128194 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29332704" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25928283" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637924" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Skin cancer is among the most costly of all cancers to treat for the Medicare population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29558557" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27455163" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sun protection for preventing basal cell and squamous cell skin cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8377777" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Reduction of solar keratoses by regular sunscreen use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475183" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17132769" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34379745" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sunscreens With High Versus Low Sun Protection Factor and Cutaneous Squamous Cell Carcinoma Risk: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29331386" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Guidelines of care for the management of cutaneous squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30497667" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cutaneous Squamous Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31084723" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11340613" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Retinoid chemoprevention in patients at high risk for skin cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9367069" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3287161" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1293159" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chemoprevention of skin cancer in xeroderma pigmentosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233316" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837863" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512910" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232634" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of long-term intake of retinol on selected clinical and laboratory indexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9367070" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15787821" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310056" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449029" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14502644" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115882" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20157019" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22644960" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25521453" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Aspirin and nonsteroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15713944" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23379978" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21050273" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Capecitabine for skin cancer prevention in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22318383" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153339" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Topical tretinoin therapy and all-cause mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28532759" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25950503" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29277731" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29299592" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30895944" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30458208" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparative effectiveness of treatment of actinic keratosis with topical fluorouracil and imiquimod in the prevention of keratinocyte carcinoma: A cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31407414" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12455062" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Vitamin and carotenoid intake and risk of squamous cell carcinoma of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31365038" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association of Vitamin A Intake With Cutaneous Squamous Cell Carcinoma Risk in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35789991" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The effect of vitamin D supplementation on risk of keratinocyte cancer: an exploratory analysis of the D-Health randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10677093" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2202901" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26488693" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21664718" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Supplement use and risk of cutaneous squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527506" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Joint effects of citrus peel use and black tea intake on the risk of squamous cell carcinoma of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21240832" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Association of tea consumption and cutaneous squamous cell carcinoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
